# Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

> **NCT04781140** · PHASE4 · RECRUITING · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 286 (estimated)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** 100mg SPN-812
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04781140
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-19
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781140, "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04781140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*